Kotak Alternate Asset Managers Ltd (Kotak Alts), through its Kotak Life Sciences Fund I (KLSF-I), invested Rs 40 crore, while Alkemi Growth Capital, a healthcare and consumer wellness-focused venture fund, invested Rs 25 cr, as per a release.

Cipher-Plexus acted as the exclusive financial advisor to the transaction. 

ZeroHarm will also invest in national brand building, international expansion across the US, UK and the Middle East, and scaling its vertically integrated R&D and manufacturing ecosystem.